中国药品许可发展趋势：从引进到走出去。

IF 9.1 2区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmacological research Pub Date : 2024-11-01 DOI:10.1016/j.phrs.2024.107488

Yale Jiang , Guo Zhao , Linlin Jia , Cheng Li , Xin Wang , Jing Cai , Huiyao Huang , Shuhang Wang , Ning Li

{"title":"中国药品许可发展趋势：从引进到走出去。","authors":"Yale Jiang , Guo Zhao , Linlin Jia , Cheng Li , Xin Wang , Jing Cai , Huiyao Huang , Shuhang Wang , Ning Li","doi":"10.1016/j.phrs.2024.107488","DOIUrl":null,"url":null,"abstract":"<div><h3>Summary</h3><div>Global medicine R&D has shown a stabilized trend after fleeting prosperity lately. Despite of discouraging whole picture, the role of China in cross-border out-licensing activities of medical therapeutics keeps rising, which started since 2020 and further boosted in 2023. A holistic analysis of drug and technology licensing, involving Chinese enterprises from 2019 to 2023, revealed 807 license-in deals and 401 license-out deals. In-licensing showed a decreasing trend, while out-licensing was the opposite. Increasing ingenuity of Chinese products has led to a shift from an import-oriented to an export-oriented situation, such as antibody-drug-conjugates, and cell/gene therapies. With supportive policies of Chinese government, southeast Asia is becoming an important downstream market for out-licensed drugs. Biotech innovators are emerging as a dominant force with core innovation capacity. China is embracing international collaboration by showing favorable markets and high-level innovative products.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"210 ","pages":"Article 107488"},"PeriodicalIF":9.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends of drug licensing in China: from bring-in to go-global\",\"authors\":\"Yale Jiang , Guo Zhao , Linlin Jia , Cheng Li , Xin Wang , Jing Cai , Huiyao Huang , Shuhang Wang , Ning Li\",\"doi\":\"10.1016/j.phrs.2024.107488\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Summary</h3><div>Global medicine R&D has shown a stabilized trend after fleeting prosperity lately. Despite of discouraging whole picture, the role of China in cross-border out-licensing activities of medical therapeutics keeps rising, which started since 2020 and further boosted in 2023. A holistic analysis of drug and technology licensing, involving Chinese enterprises from 2019 to 2023, revealed 807 license-in deals and 401 license-out deals. In-licensing showed a decreasing trend, while out-licensing was the opposite. Increasing ingenuity of Chinese products has led to a shift from an import-oriented to an export-oriented situation, such as antibody-drug-conjugates, and cell/gene therapies. With supportive policies of Chinese government, southeast Asia is becoming an important downstream market for out-licensed drugs. Biotech innovators are emerging as a dominant force with core innovation capacity. China is embracing international collaboration by showing favorable markets and high-level innovative products.</div></div>\",\"PeriodicalId\":19918,\"journal\":{\"name\":\"Pharmacological research\",\"volume\":\"210 \",\"pages\":\"Article 107488\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacological research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S104366182400433X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104366182400433X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

近来，全球医药研发在昙花一现的繁荣之后呈现出趋于稳定的态势。尽管整体形势不容乐观，但中国在医药治疗跨境许可活动中的作用却在不断提升，这一趋势自2020年开始，并在2023年进一步增强。对 2019 年至 2023 年涉及中国企业的药物和技术许可进行的全面分析显示，共有 807 项许可进入交易和 401 项许可退出交易。授权内交易呈下降趋势，授权外交易则相反。中国产品的独创性不断提高，导致从进口导向转向出口导向，如抗体-药物共轭物和细胞/基因疗法。在中国政府的支持政策下，东南亚正成为外授权药品的重要下游市场。生物技术创新企业正在成为具有核心创新能力的主导力量。中国正通过展示有利的市场和高水平的创新产品来迎接国际合作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Trends of drug licensing in China: from bring-in to go-global

查看原文本刊更多论文

Trends of drug licensing in China: from bring-in to go-global

Summary

Global medicine R&D has shown a stabilized trend after fleeting prosperity lately. Despite of discouraging whole picture, the role of China in cross-border out-licensing activities of medical therapeutics keeps rising, which started since 2020 and further boosted in 2023. A holistic analysis of drug and technology licensing, involving Chinese enterprises from 2019 to 2023, revealed 807 license-in deals and 401 license-out deals. In-licensing showed a decreasing trend, while out-licensing was the opposite. Increasing ingenuity of Chinese products has led to a shift from an import-oriented to an export-oriented situation, such as antibody-drug-conjugates, and cell/gene therapies. With supportive policies of Chinese government, southeast Asia is becoming an important downstream market for out-licensed drugs. Biotech innovators are emerging as a dominant force with core innovation capacity. China is embracing international collaboration by showing favorable markets and high-level innovative products.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacological research 医学-药学

CiteScore

18.70

自引率

3.20%

发文量

491

审稿时长

8 days

期刊介绍： Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.